ABIM Cardiovascular Disease Review: Essential Cardiology for Certification

Success on the American Board of Internal Medicine (ABIM) Certification Exam requires a sophisticated command of cardiovascular medicine, as this specialty represents approximately 14% of the total exam content. This ABIM cardiovascular disease review provides the conceptual framework and clinical depth necessary to navigate the complexities of modern cardiology. Candidates must move beyond simple rote memorization, instead focusing on the application of evidence-based guidelines to specific patient scenarios. The exam prioritizes the ability to differentiate between similar clinical presentations, such as the various etiologies of chest pain or the nuances of heart failure phenotypes. By mastering the diagnostic algorithms, pharmacologic interventions, and risk-stratification tools discussed herein, examinees can approach the cardiology section with the confidence required for high-level performance and clinical proficiency in an internal medicine setting.

ABIM Cardiovascular Disease Review: Core Principles and High-Yield Focus

The Weight of Cardiology on the Exam

Cardiology is the single largest subspecialty on the cardiology ABIM exam, making it the cornerstone of a successful study plan. The ABIM blueprint allocates a significant portion of questions to this domain because cardiovascular conditions are ubiquitous in both inpatient and outpatient internal medicine practice. Scoring well requires an understanding of the weighted blueprint, which emphasizes common conditions like hypertension and coronary artery disease over rare congenital defects. Examiners often utilize a "next best step in management" format, where multiple plausible options are presented, but only one aligns with the most current society guidelines. Candidates should expect a mix of chronic disease management and acute, life-threatening emergencies, necessitating a mental shift between the longitudinal care of a patient with stable angina and the rapid-fire decision-making required for a patient in cardiogenic shock.

Linking Pathophysiology to Clinical Presentation

To excel on the boards, one must bridge the gap between underlying physiological mechanisms and their outward clinical manifestations. For example, understanding the Frank-Starling mechanism is not just an academic exercise; it is essential for interpreting why a patient with acute decompensated heart failure might initially maintain a normal blood pressure despite a low cardiac index. The exam frequently tests the recognition of physical exam findings that correlate with specific hemodynamics, such as the presence of a pulsus paradoxus exceeding 10 mmHg as a sign of cardiac tamponade. By internalizing the relationship between pressure-volume loops and valvular pathology, candidates can deduce the correct diagnosis even when a clinical vignette presents atypical or subtle findings. This mechanical reasoning is particularly useful for questions involving complex multi-organ interactions, such as the cardiorenal syndrome.

Essential Diagnostic Modalities

Diagnostic accuracy on the ABIM exam hinges on the appropriate selection and timing of testing. The board frequently tests the pre-test probability framework, asking whether a patient requires a non-invasive stress test or should proceed directly to invasive angiography. Candidates must be proficient in ABIM ECG interpretation, identifying patterns such as the S1Q3T3 sign of pulmonary embolism or the diffuse ST-segment elevation of pericarditis. Furthermore, understanding the limitations of diagnostic tools is as important as knowing their indications. For instance, a B-type natriuretic peptide (BNP) level may be falsely low in obese patients or elevated in the setting of renal failure, a nuance often exploited in exam distractors. Mastery of the echo-Doppler assessment of valvular gradients and the use of cardiac MRI for infiltrative cardiomyopathies are also high-yield areas for the advanced candidate.

Ischemic Heart Disease and Acute Coronary Syndromes

Stable Angina vs. ACS: Diagnosis and Initial Management

Differentiating between chronic stable angina and acute coronary syndrome (ACS) is a fundamental skill for ischemic heart disease internal medicine boards preparation. The distinction relies heavily on the clinical history—specifically the tempo of symptoms and their relationship to exertion—and the presence of objective markers of myocardial injury. In the setting of ACS, the exam focuses on the rapid administration of dual antiplatelet therapy (DAPT) and the selection of the appropriate P2Y12 inhibitor. For NSTEMI, the TIMI or GRACE risk scores are used to determine the urgency of invasive intervention. Conversely, for stable angina, the emphasis shifts to optimizing anti-anginal therapy (beta-blockers, calcium channel blockers, or nitrates) and identifying high-risk features on non-invasive testing that warrant a transition to revascularization.

Post-MI Care and Secondary Prevention

Management does not end with the successful opening of an occluded vessel; the post-MI period is a critical phase heavily tested on the ABIM exam. Candidates must be familiar with the secondary prevention bundle, which includes high-intensity statins, ACE inhibitors (especially for patients with an EF < 40%), and beta-blockers. The duration of DAPT is a common point of inquiry, requiring knowledge of the trade-off between ischemic protection and bleeding risk. Additionally, the exam covers the recognition of post-MI mechanical complications, such as ventricular septal rupture or papillary muscle rupture leading to acute mitral regurgitation. These are typically presented as a new holosystolic murmur and sudden hemodynamic collapse 3 to 7 days following a myocardial infarction, requiring immediate surgical consultation.

Role of Stress Testing and Coronary Imaging

Selecting the correct stress testing modality is a frequent exam scenario. The decision is based on the patient's baseline ECG and their functional capacity. If the baseline ECG is uninterpretable (e.g., LBBB or pre-excitation), an imaging component—either stress echocardiography or nuclear myocardial perfusion imaging (MPI)—is mandatory. For patients unable to exercise, pharmacologic stress with vasodilators like regadenoson is the preferred choice. The ABIM also tests the utility of Coronary Artery Calcium (CAC) scoring in the intermediate-risk patient to further refine risk and guide statin initiation. Understanding when to use Coronary CT Angiography (CCTA) for its high negative predictive value in low-to-intermediate risk patients presenting with chest pain is another contemporary topic that appears on the boards.

Heart Failure: From Diagnosis to Guideline-Directed Therapy

Differentiating HFrEF, HFpEF, and Right-Sided Failure

Heart failure is categorized by the left ventricular ejection fraction (LVEF), and the exam requires precise management for each subtype. Heart failure ABIM topics frequently involve the distinction between heart failure with reduced ejection fraction (HFrEF, LVEF ≤ 40%) and heart failure with preserved ejection fraction (HFpEF, LVEF ≥ 50%). While HFrEF has a robust evidence base for life-prolonging therapies, HFpEF management focuses on blood pressure control and the use of SGLT2 inhibitors, which have recently shown benefit across the spectrum of EF. Right-sided heart failure is often presented in the context of pulmonary hypertension or chronic lung disease, with physical exam findings like jugular venous distention and peripheral edema predominating over pulmonary congestion. Recognizing the "wet and cold" hemodynamic profile in cardiogenic shock is also essential for inpatient-focused questions.

Pharmacologic Management Algorithms for HFrEF

The modern "four pillars" of Guideline-Directed Medical Therapy (GDMT) are central to the ABIM heart failure curriculum. This includes ACE inhibitors/ARBs or, preferably, an Angiotensin Receptor-Neprilysin Inhibitor (ARNI), evidence-based beta-blockers (carvedilol, metoprolol succinate, or bisoprolol), Mineralocorticoid Receptor Antagonists (MRAs), and SGLT2 inhibitors. The exam tests the sequential initiation and titration of these agents, as well as the management of side effects like hyperkalemia or worsening renal function. Candidates should also know the specific indications for adding hydralazine and isosorbide dinitrate in self-identified Black patients with persistent symptoms. The goal of GDMT is not just symptom relief but the reduction of mortality and hospitalization, a key distinction when choosing the "most appropriate" next step in a treatment algorithm.

Diuretic Management and Volume Assessment

Effective volume management is the cornerstone of symptomatic treatment in heart failure. The ABIM exam tests the nuances of loop diuretic therapy, including the concept of the diuretic threshold and the strategy of "sequential nephron blockade" using thiazide-like diuretics for diuretic resistance. Candidates must be able to assess volume status using physical exam markers like the hepatojugular reflux and interpret the significance of a "flat" versus "distended" IVC on bedside ultrasound. Questions may also involve the management of the "cardiorenal syndrome," where the challenge is to balance aggressive diuresis with the risk of acute kidney injury. Understanding that a modest rise in serum creatinine during diuresis is often acceptable—and even expected—in the pursuit of clinical decongestion is a high-yield clinical pearl.

Hypertension and Lipid Management in Primary Care

ACC/AHA Hypertension Staging and Treatment Goals

The hypertension guidelines for ABIM align with the 2017 ACC/AHA framework, which defines Stage 1 hypertension as 130–139/80–89 mmHg and Stage 2 as ≥140/90 mmHg. The exam focuses on the appropriate threshold for initiating pharmacotherapy, which depends on the patient's calculated 10-year ASCVD risk. For those with a risk ≥10% or with established CVD, DM, or CKD, the goal is typically <130/80 mmHg. The choice of initial agent—ACE inhibitors, ARBs, Calcium Channel Blockers (CCBs), or thiazide diuretics—is often dictated by comorbidities. For example, ACE inhibitors are preferred in patients with proteinuria, while CCBs or thiazides are often more effective as first-line agents in the Black population. Proper blood pressure measurement technique, including the use of out-of-office monitoring to rule out "white coat" or "masked" hypertension, is also frequently assessed.

Statin Therapy Indications Based on ASCVD Risk

Lipid management on the ABIM exam is driven by the ASCVD Risk Estimator Plus. Candidates must know the four "statin benefit groups": individuals with clinical ASCVD, those with LDL-C ≥ 190 mg/dL, adults aged 40–75 with diabetes, and those aged 40–75 with a 10-year risk ≥ 7.5%. The exam often asks whether to initiate a moderate-intensity or high-intensity statin (e.g., Atorvastatin 40–80 mg or Rosuvastatin 20–40 mg). For patients who do not achieve the desired LDL reduction on maximally tolerated statins, the addition of Ezetimibe or a PCSK9 inhibitor is the next step according to the 2018 guidelines. The role of "risk enhancers"—such as family history, chronic kidney disease, or inflammatory conditions—in tipping the scales toward treatment in intermediate-risk patients is another common exam theme.

Management of Resistant Hypertension

Resistant hypertension is defined as blood pressure that remains above goal despite the use of three antihypertensive agents of different classes, one of which is a diuretic. The ABIM exam tests the systematic approach to these patients, starting with the exclusion of "pseudo-resistance" due to non-adherence or the white coat effect. Once confirmed, the diagnostic workup shifts toward secondary causes of hypertension, such as primary aldosteronism (tested via the aldosterone-to-renin ratio), renal artery stenosis, or obstructive sleep apnea. Pharmacologically, the addition of a Mineralocorticoid Receptor Antagonist like spironolactone is often the most effective fourth-line agent. Candidates must also be aware of the medications that can exacerbate hypertension, such as NSAIDs, decongestants, and oral contraceptives, which should be discontinued if possible before escalating therapy.

Arrhythmia Recognition and Management for the Internist

Atrial Fibrillation: Rate vs. Rhythm Control and Anticoagulation

Atrial fibrillation (AF) is a staple of the ABIM exam, requiring a dual-pronged management strategy: stroke prevention and symptom control. Stroke risk is determined using the CHA2DS2-VASc score, with anticoagulation generally recommended for a score ≥ 2 in men or ≥ 3 in women. The exam emphasizes the use of Direct Oral Anticoagulants (DOACs) over warfarin due to their superior safety profile, except in cases of moderate-to-severe mitral stenosis or mechanical heart valves. For symptom management, the choice between rate control (using beta-blockers or nondihydropyridine CCBs) and rhythm control (using antiarrhythmics or ablation) is based on the patient's symptoms and comorbidities. It is important to remember that rhythm control has not traditionally shown a mortality benefit over rate control, though recent data in early AF management have begun to influence clinical practice.

Recognizing Benign vs. Dangerous Arrhythmias on ECG

Candidates must be able to rapidly distinguish between supraventricular tachycardias (SVT) and ventricular arrhythmias. A key skill is the interpretation of the wide-complex tachycardia, where features like AV dissociation, fusion beats, and capture beats point toward Ventricular Tachycardia (VT) rather than SVT with aberrancy. On the more benign end of the spectrum, recognizing the "short-long-short" sequence that triggers Torsades de Pointes in the setting of a prolonged QT interval is critical. The exam also covers bradyarrhythmias, particularly the distinction between Mobitz Type I (Wenckebach) and Mobitz Type II second-degree AV block. Mobitz II is characterized by a constant PR interval before a dropped beat and carries a much higher risk of progression to complete heart block, necessitating a permanent pacemaker.

Indications for Pacemaker and ICD Therapy

The indications for device therapy are strictly defined by guidelines and are frequently tested. An Implantable Cardioverter-Defibrillator (ICD) is indicated for primary prevention in patients with an LVEF ≤ 35% and NYHA Class II or III symptoms despite at least 90 days of optimal GDMT (or 40 days post-MI). For patients with a wide QRS complex (>150 ms) and LVEF ≤ 35%, Cardiac Resynchronization Therapy (CRT) is indicated to improve symptoms and survival. Permanent pacemakers are required for symptomatic bradycardia or high-grade AV block. The ABIM exam may present a patient who meets these criteria and ask for the "most appropriate intervention," requiring the candidate to recognize that medical therapy must be optimized before a device is implanted, unless the patient has survived a sudden cardiac arrest (secondary prevention).

Valvular Heart Disease and Cardiac Murmurs

Identifying Classic Murmurs and Their Etiologies

Physical exam skills remain a high-yield focus on the ABIM boards. Candidates must identify the harsh systolic crescendo-decrescendo murmur of Aortic Stenosis (AS), which radiates to the carotids, and the holosystolic murmur of Mitral Regurgitation (MR), which radiates to the axilla. The exam often includes maneuvers to differentiate murmurs; for instance, the murmur of Hypertrophic Cardiomyopathy (HCM) increases with Valsalva or standing (decreased preload), while the murmur of AS decreases. Diastolic murmurs, such as the blowing decrescendo of Aortic Regurgitation or the low-pitched rumbling of Mitral Stenosis, are almost always pathologic and require further evaluation with echocardiography. Recognizing the opening snap of mitral stenosis and how its timing relative to S2 correlates with the severity of the stenosis is a classic board-level question.

When to Refer for Severe Stenosis or Regurgitation

The timing of surgical or transcatheter intervention for valvular disease is a common "next step" question. For Aortic Stenosis, the classic triad of symptoms—angina, syncope, and heart failure—marks the transition to a high-risk state where Aortic Valve Replacement (AVR) is indicated. However, the exam also tests the management of asymptomatic patients with severe AS, who should be monitored closely unless they demonstrate a drop in blood pressure during exercise testing or an LVEF < 50%. In Mitral Regurgitation, the threshold for intervention is often lower, with surgery recommended for symptomatic patients or asymptomatic patients with evidence of LV dysfunction (LVEF < 60% or LV end-systolic diameter > 40 mm). The emergence of Transcatheter Edge-to-Edge Repair (TEER) for high-risk surgical candidates is also featured on contemporary exams.

Infective Endocarditis Prophylaxis Guidelines

The ABIM exam strictly follows the narrowed indications for antibiotic prophylaxis to prevent Infective Endocarditis (IE). Prophylaxis is only recommended for high-risk dental procedures in patients with the highest risk of adverse outcomes: those with prosthetic heart valves, a history of IE, certain types of congenital heart disease, or cardiac transplant recipients with valvular regurgitation. The exam frequently includes "distractor" scenarios—such as a patient with a simple mitral valve prolapse or a bicuspid aortic valve—where prophylaxis is no longer recommended. When prophylaxis is indicated, the standard regimen is a single dose of Amoxicillin 30–60 minutes before the procedure, with clindamycin or azithromycin as alternatives for those with penicillin allergies.

Peripheral Vascular and Aortic Disorders

Diagnosis and Management of Peripheral Artery Disease

Peripheral Artery Disease (PAD) is diagnosed using the Ankle-Brachial Index (ABI), with a value ≤ 0.90 being diagnostic. The ABIM exam tests the management of PAD, which focuses on cardiovascular risk reduction (high-intensity statins, antiplatelet therapy) and symptom improvement. The first-line treatment for intermittent claudication is a supervised exercise program, which has been shown to be as effective as revascularization for many patients. Pharmacologically, cilostazol may be used to improve walking distance, but it is contraindicated in patients with heart failure of any severity. For patients with critical limb ischemia—manifesting as rest pain or non-healing ulcers—urgent imaging with CT angiography or invasive angiography is required to plan for revascularization to prevent limb loss.

Recognizing and Managing Aortic Aneurysm

Screening and surveillance for Abdominal Aortic Aneurysm (AAA) is a high-yield preventive medicine topic. The USPSTF recommends a one-time screening ultrasound for men aged 65–75 who have ever smoked. The exam tests the thresholds for intervention: an aneurysm ≥ 5.5 cm in men or ≥ 5.0 cm in women, or one that is rapidly expanding (> 0.5 cm in 6 months), warrants surgical or endovascular repair. For smaller aneurysms, the focus is on aggressive blood pressure control and smoking cessation. Thoracic aortic aneurysms are managed similarly but with different size thresholds (typically ≥ 5.5 cm unless associated with a connective tissue disorder like Marfan Syndrome). Candidates must also recognize the clinical presentation of a ruptured AAA—hypotension, back pain, and a pulsatile abdominal mass—as a surgical emergency.

Acute Aortic Syndromes: Presentation and Urgency

Acute aortic dissection is a life-threatening condition that requires rapid recognition and categorization. The Stanford classification is used to guide management: Type A involves the ascending aorta and requires emergent surgery, while Type B involves only the descending aorta and is typically managed medically with aggressive heart rate and blood pressure control. The exam often presents a patient with "tearing" chest pain radiating to the back and a pulse deficit between the arms. The initial goal is to reduce the shear stress on the aortic wall by lowering the heart rate to < 60 bpm and the systolic blood pressure to 100–120 mmHg, usually with intravenous beta-blockers like esmolol or labetalol. CT angiography is the diagnostic gold standard, but in an unstable patient, a transesophageal echocardiogram (TEE) may be performed at the bedside.